How to appeal a CareFirst BCBS adult adhd medications denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

CareFirst BCBS-specific note: BCBS licensee for Maryland, DC, and northern Virginia (~3.5M members). Operates as non-profit. Appeals jurisdiction depends on policy issue location — MIA (MD), DISB (DC), or SCC Bureau of Insurance (VA). CVS Caremark is the PBM.

What CareFirst BCBS's policy requires for adult adhd medications

Cited policy: BCBS Prior Authorization Criteria — ADHD/Stimulant Medications (varies by plan; e.g., Anthem CG-MED-ADHD, Highmark Stimulants PA)

Wide variation. Most require DSM diagnosis, prior trial of >=1 generic stimulant for brand, dose within FDA label.

How CareFirst BCBS denies adult adhd medications — and how to counter it

Where CareFirst BCBS pushes back: 1) Adult new-start denials with 'ADHD typically diagnosed in childhood'; 2) Dose cap denials for Vyvanse >70mg or Adderall XR >30mg; 3) Concurrent benzodiazepine or opioid use flagged as contraindication.

Counter-arguments that hold up: World Federation of ADHD Consensus 2021 — adult-onset recognition is valid; late diagnosis common in women and high-IQ individuals who compensated. For doses above label: peer-reviewed dose-response (Wigal et al. on Vyvanse, Spencer et al. on amphetamine) — request medical exception with clinical justification. Stimulant + benzodiazepine NOT contraindicated; only requires monitoring per FDA label.

What CareFirst BCBS typically denies for adult adhd medications

Across CareFirst BCBS's commercial and Medicare books, denials cluster around a small number of patterns. For adult adhd medications, expect:

• DC/MD/VA cross-jurisdiction issues
• Step therapy on specialty drugs via CVS Caremark
• Behavioral health network adequacy
• BlueChoice HMO referral denials

Treatments most often denied in this category

These are the adult adhd medications treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Vyvanse
• Adderall XR
• Concerta
• Focalin XR
• Ritalin LA
• Strattera

How to submit the appeal to CareFirst BCBS

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document CareFirst BCBS cited in the denial.
3. File the appeal through CareFirst BCBS's portal (members: https://member.carefirst.com ; providers: https://provider.carefirst.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MD, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See CareFirst BCBS's prior-authorization criteria by drug: CareFirst BCBS PA criteria on ApprovalHelp.